Business Summary
|
LifeCycle Pharma A/S (LCP) is a Denmark-based specialty pharmaceutical company. It focuses its activities on cardiovascular indications and organ transplantation. The Company develops drugs basing on its MeltDose reformulation technology platform, which is designed to enhance the release and absorption of drugs in the body, by incorporating the drug in a solubilized form in a tablet matrix. As of December 31, 2009, the Company’s product pipeline included 10 projects: five immunosuppression projects, three dyslipidemia projects and two preclinical projects. The Company has one commercialized product, LCP-FenoChol, which received the United States Food and Drug Administration's (FDA) approval for the treatment of hyperlipidemia and triglyceridemia and for the sale in the United States under the brand name Fenoglide. LifeCycle Pharma A/S has one wholly owned subsidiary, LifeCycle Pharma Inc, domiciled in the United States.
| | (Source: ARS)
|
|
|
